These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Christensen R; Kristensen PK; Bartels EM; Bliddal H; Astrup A Lancet; 2007 Nov; 370(9600):1706-13. PubMed ID: 18022033 [TBL] [Abstract][Full Text] [Related]
25. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant]. Boekholdt SM; Jukema JW; Peters RJ Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262 [TBL] [Abstract][Full Text] [Related]
26. Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial. O'Leary DH; Reuwer AQ; Nissen SE; Després JP; Deanfield JE; Brown MW; Zhou R; Zabbatino SM; Job B; Kastelein JJ; Visseren FL; Heart; 2011 Jul; 97(14):1143-50. PubMed ID: 21610270 [TBL] [Abstract][Full Text] [Related]
27. Depression and weight loss: opposite outcome for surgery and rimonabant? Chaput JP; Tremblay A Obes Rev; 2008 Sep; 9(5):504-7. PubMed ID: 18643944 [No Abstract] [Full Text] [Related]
28. What is the potential role of cannabinoid-1 receptor blockade in glucose and lipid management? Jensen MD Am J Med; 2007 Sep; 120(9 Suppl 1):S25-31; discussion S31-2. PubMed ID: 17720358 [TBL] [Abstract][Full Text] [Related]
29. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. Christopoulou FD; Kiortsis DN J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716 [TBL] [Abstract][Full Text] [Related]
30. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Van Gaal LF; Rissanen AM; Scheen AJ; Ziegler O; Rössner S; Lancet; 2005 Apr 16-22; 365(9468):1389-97. PubMed ID: 15836887 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491 [TBL] [Abstract][Full Text] [Related]
32. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Després JP; Ross R; Boka G; Alméras N; Lemieux I; Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):416-23. PubMed ID: 19112166 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of the weight-loss drug rimonabant. Blüher M Lancet; 2008 Feb; 371(9612):555-6; author reply 556-7. PubMed ID: 18280321 [No Abstract] [Full Text] [Related]
38. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system]. Ducobu J; Sternon J J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510 [TBL] [Abstract][Full Text] [Related]
39. Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data. Bronander KA; Bloch MJ Vasc Health Risk Manag; 2007; 3(2):181-90. PubMed ID: 17580728 [TBL] [Abstract][Full Text] [Related]
40. Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors. Cox SL Drugs Today (Barc); 2005 Aug; 41(8):499-508. PubMed ID: 16234873 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]